DexCom, Inc. (NASDAQ:DXCM) Given Average Recommendation of "Moderate Buy" by Analysts

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nineteen research firms that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $99.82.

A number of equities research analysts recently issued reports on the company. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Canaccord Genuity Group boosted their price target on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th.

DexCom Stock Down 3.7 %

Shares of DexCom stock traded down $2.66 on Monday, hitting $69.47. The company had a trading volume of 5,523,478 shares, compared to its average volume of 3,919,032. The stock has a 50-day moving average of $82.96 and a 200-day moving average of $77.07. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom has a twelve month low of $62.34 and a twelve month high of $141.99. The firm has a market capitalization of $27.15 billion, a P/E ratio of 48.58, a P/E/G ratio of 2.30 and a beta of 1.28.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts predict that DexCom will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the sale, the executive vice president now owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Hedge funds and other institutional investors have recently bought and sold shares of the company. Versant Capital Management Inc acquired a new position in shares of DexCom in the 4th quarter valued at about $25,000. Private Trust Co. NA lifted its stake in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the period. Optiver Holding B.V. bought a new position in shares of DexCom during the 4th quarter worth approximately $33,000. TD Private Client Wealth LLC grew its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the period. Finally, Larson Financial Group LLC increased its stake in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.